Novartis, CH0012005267

Novartis wins FDA approval for Rhapsido. 20 analysts rate Novartis stock Hold

Published on 10/09/2026 at 12:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rhapsido gains a second hive use after FDA approval on October 7, 2026. Novartis stock costs EUR 127.23 on October 9, 2026 versus EUR 127.20.

Key points in brief

Novartis received FDA approval for Rhapsido on October 7, 2026, expanding its use to symptomatic dermographism.
Second-quarter 2026 adjusted earnings per share reached USD 2.41 versus USD 2.18 consensus, while revenue was USD 14.41 billion versus USD 14.17 billion expected.
Novartis stock was trading at EUR 127.23 at Lang & Schwarz on October 9, 2026 at 12:17 p.m. CEST, plus 0.02 percent versus EUR 127.20.
The next listed company dates are October 23, 2026, for multiple sclerosis data, and October 27, 2026, for third-quarter results.

Extreme Nahaufnahme einer weißen Tablette mit Bruchkerbe und feiner granularer Textur — Novartis AG CH0012005267 – Extreme Makroaufnahme einer weißen Tablette mit Bruchkerbe und feiner Oberflächentextur, Illustration mit AI erstellt.

Novartis stock was trading at EUR 127.23 at Lang & Schwarz on October 9, 2026 at 12:17 p.m. CEST, plus 0.02 percent versus the EUR 127.20 prior close. On October 7, 2026, Novartis received U.S. Food and Drug Administration approval for Rhapsido, while MarketBeat listed 20 analyst ratings with a Hold consensus.

FDA approval widens Rhapsido use

According to Novartis on October 7, 2026, Rhapsido became the first treatment approved specifically for adults with symptomatic dermographism whose symptoms remain inadequately controlled by H1 antihistamines. The drug now has approved uses in symptomatic dermographism and chronic spontaneous urticaria, giving the company a broader commercial base in chronic hives.

The Phase III RemIND trial supplied the approval evidence. At Week 12, 29.30 percent of patients receiving Rhapsido achieved complete hive resolution versus 14.00 percent on placebo, a 15.30 percentage-point difference reported by Novartis in the same October 7, 2026 release.

What does the pipeline deal add?

On October 2, 2026, Novartis signed a licensing agreement with Abogen Biosciences valued at up to USD 7.80 billion. CNBC reported that the agreement includes a USD 575.00 million upfront payment and up to USD 7.20 billion in milestone payments.

The deal adds an early-stage messenger RNA therapy to the pipeline, but most of its value depends on development, regulatory and commercial milestones. That structure makes Rhapsido's regulatory expansion the more immediate operating event, while the Abogen agreement represents longer-duration pipeline optionality.

Three milestones shape the sequence

On July 21, 2026, second-quarter revenue reached USD 14.41 billion versus USD 14.17 billion consensus, and adjusted earnings per share reached USD 2.41 versus USD 2.18 expected, according to Investing.com. On October 2, 2026, the Abogen agreement carried a USD 575.00 million upfront payment and up to USD 7.20 billion in milestones, as Reuters reported. On October 7, 2026, Rhapsido delivered the current regulatory milestone with 29.30 percent complete hive resolution versus 14.00 percent placebo, according to Novartis.

What dates come next?

Novartis is scheduled to present multiple sclerosis data on October 23, 2026, including late-breaking Phase III REMODEL-1 and REMODEL-2 results, according to GlobeNewswire. The investor calendar lists October 27, 2026, for Novartis financial results for the third quarter of 2026, according to the company investor page.

Stock holds near the prior close

At Lang & Schwarz, Novartis stock was trading at EUR 127.23 on October 9, 2026 at 12:17 p.m. CEST, up EUR 0.03 or plus 0.02 percent versus the EUR 127.20 prior close on October 8, 2026. The small daily change leaves the regulatory approval, pipeline funding and upcoming results dates as the clearest measurable reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.